1. Home
  2. URG vs EVMN Comparison

URG vs EVMN Comparison

Compare URG & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ur Energy Inc (Canada)

URG

Ur Energy Inc (Canada)

HOLD

Current Price

$1.31

Market Cap

488.7M

ML Signal

HOLD

Logo Evommune Inc.

EVMN

Evommune Inc.

HOLD

Current Price

$12.88

Market Cap

405.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
URG
EVMN
Founded
2004
2020
Country
United States
United States
Employees
N/A
48
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
488.7M
405.2M
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
URG
EVMN
Price
$1.31
$12.88
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
10
Target Price
$2.57
$43.88
AVG Volume (30 Days)
6.6M
692.5K
Earning Date
05-08-2026
06-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$27,207,000.00
N/A
Revenue This Year
$200.42
N/A
Revenue Next Year
$98.46
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.12
$10.47
52 Week High
$2.35
$33.20

Technical Indicators

Market Signals
Indicator
URG
EVMN
Relative Strength Index (RSI) 48.55 46.96
Support Level $1.29 $12.07
Resistance Level $1.33 $21.21
Average True Range (ATR) 0.07 0.84
MACD 0.02 0.49
Stochastic Oscillator 71.05 84.98

Price Performance

Historical Comparison
URG
EVMN

About URG Ur Energy Inc (Canada)

Ur-Energy Inc is engaged in uranium mining and recovery operations, with activities including the acquisition, exploration, development, and production of uranium mineral resources located in Wyoming. The company owns and operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming, Lost Creek received an amendment to its license allowing the expansion of mining activities within the existing Lost Creek Project and the adjacent LC East Project; Shirley Basin; Other U.S. Projects.

About EVMN Evommune Inc.

Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.

Share on Social Networks: